for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent to make Providence Therapeutics' potential COVID-19 vaccine

Sept 14 (Reuters) - Emergent BioSolutions Inc signed a five-year agreement with Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate, the companies said on Tuesday.

The agreement signed between Emergent and Providence Therapeutics is valued at about $90 million. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up